Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Point Biopharma Global Inc (NQ: PNT )

9.410 +0.020 (+0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 458,992
Open 9.400
Bid (Size) 9.260 (1)
Ask (Size) 10.50 (1)
Prev. Close 9.390
Today's Range 9.260 - 9.650
52wk Range 5.590 - 11.13
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. 
Via Investor's Business Daily
Why Shares of Point Biopharma Global Rose Monday
The company made a deal to help speed its clinical trials along. 
Via The Motley Fool

Performance

YTD
+30.33%
+30.33%
1 Month
+21.58%
+21.58%
3 Month
+25.13%
+25.13%
6 Month
+42.79%
+42.79%
1 Year
+14.48%
+14.48%

More News

Read More
Arlo Technologies, Array Technologies, AirSculpt Technologies And Other Big Stocks Moving Higher On Friday
Via Benzinga
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
Via InvestorPlace
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
From Lantheus Holdings, Inc.; POINT Biopharma Global Inc.
Via GlobeNewswire
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
Via InvestorPlace
Earnings Scheduled For March 24, 2023
Via Benzinga
Earnings Preview: POINT Biopharma Global
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Over $16 Million Bet On Energy Transfer? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Analyst Ratings for POINT Biopharma Global
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Dow Surges 150 Points; Crude Oil Falls Sharply
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Lantheus-POINT Biopharma Ink Strategic Collaboration For Cancer Programs
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Stocks Cool Off From Last Week's Rally
Via Talk Markets
Silver Rises Over 1%; Tyson Foods Posts Downbeat Earnings
Via Benzinga
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
US Stocks Mostly Lower; Nasdaq Drops Over 100 Points
Via Benzinga
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
From Lantheus Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.